Gelomics is pleased to announce a new strategic partnership with Bucher Biotec AG, a leading provider of advanced life science solutions in Switzerland & Lichtenstein. Under this agreement, Bucher Biotec will serve as Gelomics' exclusive distributor across the Swiss market.
This partnership marks an important milestone for Gelomics as we expand our presence in Europe. With Bucher Biotec's expertise and strong network in the Swiss life sciences sector, Gelomics' advanced technologies will now be more accessible to researchers and institutions across Switzerland's leading drug development and biomedical research sectors.
"The partnership with Bucher Biotec marks a pivotal step in expanding Gelomics' global reach and supporting Swiss researchers with advanced tools for predictive and ethical drug development. Together, we aim to accelerate scientific breakthroughs and improve patient outcomes.”
Dr Christoph Meinert, CEO of Gelomics
“We are proud to join forces with Gelomics, recognized for their innovative 3D cell culture technologies. This collaboration marks a dynamic step forward in equipping researchers in Switzerland with transformative tools, advancing our shared vision of delivering cutting-edge technologies for impactful biomedical research."
Georg Kienzle, Director of Sales and Support at Bucher Biotec AG
About Gelomics
Gelomics is dedicated to revolutionising drug development and biomedical research by enabling the cultivation of human tissue models in vitro. Our mission is to accelerate therapeutic breakthroughs by providing scientists with ethical, cost-effective, and predictive alternatives to animal testing. For more information about Gelomics and our range of products, please visit https://www.gelomics.com.
About Bucher Biotec
Bucher Biotec AG is a privately held Swiss distributor company, focusing on innovative technologies for the life sciences and diagnostic markets. With over 45 years of experience, Bucher Biotec has built a reputation for delivering high-quality solutions to Swiss researchers, healthcare professionals, and institutions, enabling advancements in biomedical and life sciences research. For more information, please visit https://www.bucher.ch.
Comments